Skip to main content
锦波生物 logo

锦波生物 — Investor Relations & Filings

Ticker · 920982 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 391 across all filing types
Latest filing 2026-05-06 Investor Presentation
Country CN China
Listing Beijing Stock Exchange 920982

About 锦波生物

https://www.sxjbswyy.com/

Shanxi Jinbo Bio-Pharmaceutical Co., Ltd. specializes in the research, development, and manufacturing of functional proteins through synthetic biology. The company is recognized for its industrialization of recombinant humanized collagen, specifically Type III collagen with a stable triple helix structure. Its core business encompasses the production of medical-grade biomaterials, functional skincare products, and medical devices used in aesthetics, wound healing, and gynecological health. By utilizing advanced protein engineering, the company provides biocompatible solutions designed for tissue repair and anti-aging applications. Its technical focus remains on the structural optimization and large-scale production of high-purity recombinant proteins to meet clinical and consumer health demands.

Recent filings

Filing Released Lang Actions
2025年年度报告暨2026年一季度报告业绩说明会预告公告
Investor Presentation Classification · 95% confidence The document is a short announcement (1016 characters) about a scheduled performance explanation meeting (业绩说明会) for the 2025 Annual Report and 2026 Q1 Report. It references that the actual 2025 Annual Report and 2026 Q1 Report have already been disclosed previously with specific announcement numbers. The document provides details about the meeting time, location, participants, and how investors can join and submit questions. It does not contain any financial data or the reports themselves, but rather announces the upcoming investor presentation event related to those reports. According to the 'Menu vs Meal' rule, this is an announcement about a report-related event, not the report itself. Therefore, the appropriate classification is Investor Presentation (IP).
2026-05-06 Chinese
2025年年度权益分派预案公告
Notice of Dividend Amount Classification · 95% confidence The document is titled as an "Annual Equity Distribution Plan Announcement" for the year 2025 by Shanxi Jinbo Biopharmaceutical Co., Ltd. It discusses the company's proposed dividend distribution plan based on the audited 2025 annual report, including details on cash dividends per share, retained earnings, and the approval process involving the board and shareholders. The document also references the company's dividend policies, past dividend history, and legal compliance. The text is an announcement of a dividend distribution plan (权益分派预案公告) rather than the full annual report or financial statements. It is relatively short (3824 characters) and serves as a formal notice of the dividend proposal pending shareholder approval. Therefore, it fits best under the category "Notice of Dividend Amount" (DIV), which covers announcements of dividend amounts, payment dates, and related details for shareholders.
2026-04-28 Chinese
关于调整2025年股票期权激励计划行权价格的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from Shanxi Jinbo Biopharmaceutical Co., Ltd. regarding the adjustment of the exercise price of the 2025 stock option incentive plan. It details the approval process, reasons for adjustment, adjustment methods, and the impact on the company. The document includes references to board meetings, shareholder meetings, legal opinions, and financial advisor opinions related to the stock option plan. It is not a full financial report, earnings release, or management discussion but a specific announcement about a capital/financing related update (stock option exercise price adjustment). The document length is 4497 characters, which is sufficient for a detailed announcement but not a full report. Therefore, it fits best under Capital/Financing Update (CAP).
2026-04-28 Chinese
关于山西锦波生物医药股份有限公司注销2025年股票期权激励计划部分股票期权的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the cancellation of part of a 2025 stock option incentive plan for Shanxi Jinbo Biopharmaceutical Co., Ltd. It references specific corporate governance procedures, approvals by the board and shareholders, and compliance with relevant laws and regulations. The document is not a financial report, earnings release, or regulatory filing per se, but a legal opinion related to a corporate action involving stock options. It does not contain financial statements or earnings data, nor is it a simple announcement or certification. The content fits best under the category of Regulatory Filings (RNS) as it is a legal opinion document related to corporate governance and compliance, which does not fit other more specific categories.
2026-04-28 Chinese
中汇会计师事务所（特殊普通合伙）2025年度履职情况评估报告
Audit Report / Information Classification · 95% confidence The document is an evaluation report on the performance of the auditing firm Zhonghui CPA Firm for the fiscal year 2025. It details the auditor's qualifications, the audit procedures, and the company's assessment of the auditor's work. It does not contain the full annual report or financial statements but focuses on the auditor's role and performance. The document is titled as an evaluation report related to audit work and does not present financial results or management discussion. Therefore, it fits the category of an Audit Report / Information (AR). The document length is short (1266 characters), but it contains substantive content about audit performance, not just an announcement or certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA). FY 2025
2026-04-28 Chinese
中信证券股份有限公司关于山西锦波生物医药股份有限公司使用闲置自有资金购买理财产品的核查意见
Regulatory Filings Classification · 95% confidence The document is a verification opinion from a sponsoring institution (中信证券股份有限公司) regarding the use of idle funds by 山西锦波生物医药股份有限公司 to purchase wealth management products. It discusses the purpose, amount, risk analysis, decision-making procedures, and the sponsoring institution's opinion on the matter. The document is regulatory in nature, related to compliance and supervisory review, and does not contain financial statements or detailed financial results. It is not an annual report, interim report, earnings release, or any direct financial report. It is also not a simple announcement of a report publication. The document fits best as a Regulatory Filing (RNS) because it is a compliance-related verification opinion required by securities regulations and listing rules, without substantive financial data or report content.
2026-04-28 Chinese

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.